Clinical trial Recruiting at 1 site Observational

Cap-assisted endoscopic sclerotherapy for treating internal hemorrhoids and rectal prolapse

Official title: Cap-assisted Endoscopic Sclerotherapy for Internal Hemorrhoids and Rectal Prolapse: a National Multi-centre Prospective Cohort Study

Run by The Second Hospital of Nanjing Medical University · NCT04169152 · Data updated 2026-11-12

This study is testing a new method using a special cap during sclerotherapy to see if it can safely and effectively treat people with internal hemorrhoids and rectal prolapse.

Quick facts

Study typeObservational
SexAll
Enrollment10000 (estimated)
SponsorThe Second Hospital of Nanjing Medical University
Academic / other
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedDecember 30, 2019
Main results expectedDecember 30, 2027
Study endsJune 30, 2028
Registry record updatedApril 2, 2024
Trial IDNCT04169152 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with Grade I-III internal hemorrhoids or rectal prolapse who have undergone bowel preparation.

Probably not a fit

Patients with severe complications such as acute thrombotic hemorrhoids, inflammatory bowel disease, or those who are pregnant may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the efficacy and safety of cap-assisted endoscopic sclerotherapy (CAES) for patients with internal hemorrhoids and rectal prolapse. The innovative procedure utilizes a cap on the colonoscope to enhance visibility and precision during treatment, allowing for accurate injections while minimizing patient discomfort and potential complications. The study aims to gather large-scale data to confirm the long-term effectiveness of CAES, building on promising pilot results that showed sustained clinical efficacy within three months and no severe complications. By conducting this nationwide multi-center study, researchers hope to provide reliable evidence for the broader adoption of this minimally invasive technique.

Why it matters

Potential benefit: If successful, this approach could offer a safer and more effective treatment option for patients suffering from internal hemorrhoids and rectal prolapse.

How similar studies have gone: While pilot studies have shown promising results for CAES, this nationwide study aims to confirm its long-term efficacy and safety, making it a significant step in evaluating this novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Grade I-III internal hemorrhoids (with or without external hemorrhoids) or/and recal prolapse.
2. Patients with bowel preparation.

Exclusion Criteria:

1. History of anoscopic/endoscopic sclerotherapy.
2. Acute thrombotic hemorrhoids or grade IV internal hemorrhoids.
3. Anal stenosis, perianal and perirectal abscess, anal fissure, fistula, fecal incontinence and other severe complications (such as severe anal pain).
4. Inflammatory bowel disease.
5. Full-thickness rectal prolapse through the anus.
6. Acute diarrhea in the past 24 hours.
7. Hypertensive with uncontrolled blood pressure.
8. Cerebrovascular accident.
9. Blood coagulation dysfunction.
10. Pregnant women.
11. Mental disorders.
12. Decompensated cirrhosis.

Where it's running

  • Medical Center for Digestive Diseases, Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.